Symptomatic therapy for acute infectious and inflammatory diseases of the pharynx

Abstract

Improving the effectiveness of treatment of patients with acute infectious and inflammatory pharyngeal diseases remains one of the topical issues facing the modern healthcare practice covering otorhinolaryngology, paediatrics and internal medicine sectors. The authors described the clinical picture of acute tonsillopharyngitis of various origin, and pharyngeal presentations in novel coronavirus infection. The article summarizes the modern principles of topical and systemic therapy in infectious and inflammatory pharyngeal pathology according to different etiological factors. Expedience of using topical antiseptic drugs as symptomatic therapy has been substantiated. The article examines in detail topical drugs that allow to achieve the maximum active substance concentration of the site of inflammation without systemic effect on the patient. The therapeutic options of topical antiseptic drugs are demonstrated using the example of Faringazon (active substance – ambazon) with local bacteriostatic effects against gram-positive microorganisms: Streptococcus haemolyticus, Streptococcus viridans, Pneumococcus. Most patients with inflammatory pharyngeal diseases do not require systemic antimicrobial therapy, therefore the local effect that can relieve local symptoms of the disease, return the pharyngoscopic picture to normal and improve patients’ general well-being is the main method of treatment. Symptomatic topical therapy as a component of care bundle for acute infectious and inflammatory pharyngeal diseases can significantly ease patients’ condition, reduce the intensity of pain syndrome and accelerate the eradication of pathogens. The use of Faringazon in wide clinical practice is justified owing to its efficiency and ease of administration. It is necessary to emphasize that Faringazon does not cause GI side effects. Exceptions are cases when the patients have individual intolerance to the active substance.